SPRB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Spruce Biosciences, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 42.83 USD
-0.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -27.2% below the Trend Line and sits at 15.4% of its 52-week range. The latest completed week returned -0.6%, after a -18.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 16 out of 100
Latest Close 42.83 USD 31 Jul 2026
1W Return -0.6% latest completed week
4W Return -18.4% short-term follow-through
12W Return -24.2% quarterly tape
Trend Breadth 36.5% 19 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.6% Latest completed week; four-week move -18.4%. Indicator stack 20/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 43 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -27.2% below the Trend Line and sits at 15.4% of its 52-week range. The latest completed week returned -0.6%, after a -18.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1212-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -18.4% over four weeks, -24.2% over 12 weeks, and 423.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-0.6%
4W-18.4%
12W-24.2%
26W-44.8%
52W423.9%
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.42Latest activity-pressure read.
Pressure change-527.6%Four-week change in activity pressure.
Leadership-37.98Latest relative-leadership reading.
RS change-60.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength36/100Blend of value, momentum, and quality. Underlying universe rank 65; rank 1 is best.
Value43/100Relative valuation strength. Underlying universe rank 58; rank 1 is best.
Quality42/100Profitability and accounting quality. Underlying universe rank 59; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth44/100Revenue and earnings growth. Underlying universe rank 57; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-40.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-42.2%
Net share repurchases relative to market value.
Shareholder yield
-42.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 43 relevant articles.

7 positive · 35 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-82.2%Distance below the 52-week high.
13-week volatility4.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+11.8%Week of 3 Apr.
Worst week-25.0%Week of 20 Feb.
Latest week-0.6%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks0
Modest losses5
Sharp losses10
Recent vol4.4%13-week weekly-return volatility.
Base vol257.1%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew99.1% / -9.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis11/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.12; No reversal markers Factors40/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 58 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 43 relevant articles.

BlackRock, Inc. (SPRB) reports 6.8% beneficial ownership in Spruce Biosciences Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202642.83 USD-0.6%58.79 USD73.73 USD-1.42-37.98258.3KOff
24 Jul 202643.08 USD-1.1%60.39 USD74.56 USD-1.19-36.70266.6KOff
17 Jul 202643.54 USD-13.0%61.81 USD75.37 USD-0.70-36.47448.8KOff
10 Jul 202650.07 USD-4.6%62.99 USD76.15 USD-0.45-29.32281.8KOff
3 Jul 202652.51 USD-4.7%64.10 USD76.83 USD-0.23-23.68306.0KOff
26 Jun 202655.11 USD5.3%65.01 USD77.52 USD-0.16-18.17660.4KOff
19 Jun 202652.36 USD0.9%66.51 USD78.20 USD-0.28-24.71375.1KOff
12 Jun 202651.89 USD2.9%68.26 USD78.98 USD-0.26-22.43258.2KOff
5 Jun 202650.43 USD-1.6%70.08 USD79.79 USD-0.30-21.88230.8KOff
29 May 202651.27 USD0.4%72.63 USD80.58 USD-0.31-23.15184.8KOff
22 May 202651.08 USD-5.0%74.59 USD81.37 USD-0.37-20.21346.8KOff
15 May 202653.78 USD-4.8%77.33 USD82.21 USD-0.35-13.81209.6KOff
8 May 202656.50 USD-1.4%80.80 USD82.99 USD-0.28-8.41169.3KOff
1 May 202657.28 USD5.4%84.70 USD83.70 USD-0.32-0.54301.7KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.